Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels

• Autors principals: Ting Chen (Autor), Yulong Zhang (Autor), Manyun Chen (Autor), Pu Yang (Autor), Yi Wang (Autor), Wei Zhang (Autor), Weihua Huang (Autor)
• Format: Llibre
• Publicat: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

AbstractContext The Tongmai Yangxin pill (TMYX) has potential clinical effects on no-reflow (NR); however, the effective substances and mechanisms remain unclear.Objective This study evaluates the cardioprotective effects and molecular mechanisms of TMYX against NR.Materials and methods We used a my...